Pharmacological Comparison of Antipsychotic Drugs and σ‐Antagonists in Rodents
- 1 September 1994
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 75 (3-4) , 222-227
- https://doi.org/10.1111/j.1600-0773.1994.tb00351.x
Abstract
We compared antipsychotic drugs (haloperidol, chlorpromazine and clozapine) and σ antagonists (remoxipride, cinuperone, α‐(4‐fluorophenyl)‐4‐(‐fluoro‐2‐pyrimidinyl)‐1‐piperazine butanol (BMY 14802) and rimcazole) in the radioligand binding and behavioural experiments in rodents. A good correlation was established between the affinity of compounds at dopamine2‐receptors in the striatum and their ability to block apomorphine‐, amphetamine‐ and quipazine‐induced behavioural effects in rodents. By contrast, no correlation was found between the behavioural effects of these drugs and their affinity at dopamine1‐, 5‐HT2‐ and a receptors. The rank order of potency among the studied antipsychotic drugs in the behavioural tests and at dopamine2‐receptors was following: haloperidol≫chlorpromazine≥clozapine. The effectiveness of chlorpromazine and clozapine was nearly similar against apomorphine‐induced aggressiveness and yawning, whereas at 5‐HT2‐receptors clozapine was more active than chlorpromazine. The weak activity of σ antagonists at dopamine2receptors could be a possible reason why these compounds were less effective in the behavioural studies compared to antipsychotic drugs. However, the antagonism of remoxipride against apomorphine‐induced stereotypy and aggressiveness is not related to its activity at σ receptors, because the other σ antagonists did not block these effects of apomorphine. It is probable that remoxipride exerts its action through blocking of dopamine2receptors. In conclusion, the present study revealed only weak activity of σ antagonists in the behavioural models widely used to study the antipsychotic drugs. Therefore, the antipsychotic activity of σ antagonists is doubtful.Keywords
This publication has 31 references indexed in Scilit:
- BMY-14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving ratsSynapse, 1992
- Rat cortical sigma receptors differentially regulated by pentazocine and haloperidolJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Non-competitive antagonists are potent activators of ventral tegmental A10 dopamine neuronsNeuroscience Letters, 1990
- MK-801-induced stereotypy and its antagonism by neuroleptic drugsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1990
- Up-regulation of rat cortical σ receptors after subchronic administration of rimcazole and 1,3-di(2-tolyl)guanidineNeuropharmacology, 1988
- HR 375: A potential antipsychotic drug that interacts with dopamine D2 receptors and σ-receptors in the brainNeuroscience Letters, 1986
- Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brainLife Sciences, 1986
- BW234U,(cis-9-[3–(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agentJournal of Pharmacy and Pharmacology, 1982
- Head twitches induced by LSD and quipazine: Similarities and differencesNeuropharmacology, 1980
- Antipsychotic drug doses and neuroleptic/dopamine receptorsNature, 1976